Company
Headquarters: Taipei, Taiwan
Employees: 15
CEO: Mr. Chen Bryon
TW$1.38 Billion
TWD as of Jan. 1, 2024
US$44.9 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, other vaccines, etc. The company was founded in 1995 and is based in Taipei, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Advagene Biopharma Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6709 wb_incandescent